Search PubMed⌕ Search

Biomedical subjects

A Segaloff

Publications and source records attributed to A Segaloff.

At least 37 records · Page 2Linked to original sources
PubMed1978

Plasma immunoreactive relaxin levels in pregnant and nonpregnant women.

Immunoreactive relaxin was measured in plasma samples obtained from human volunteers utilizing the RIA procedure of Sherwood et al., as modified by O'Byrne and Steinetz for heterologous plasma samples. Immunoreactive hormone was not detected in samples obtained from men, and only rarely in plasma of nonpregnant women. Immunoreactive relaxin was present as early as the fourth week of pregnancy and was detectable throughout the course of gestation. Immunoreactive relaxin tended to be higher early in pregnancy, and there was no peak just before parturition as occurs in many other species. Our results are at variance with those of Bryant and coworkers, who reported high levels of immunoreactive relaxin in men and nonpregnant as well as pregnant women. The possible reasons for this discrepancy are presented.

Contraceptives, Oral, Combined↗
PubMed1977

Current status of estrogen and progesterone receptors in breast cancer.

Breast cancer is often hormone responsive, since growth or regression of tumors can often be modulated by appropriate endocrine manipulations. Estrogen and progesterone appear to be major hormones involved in regulation of breast tumor growth. It has been recently argued that a more accurate marker of hormonal responsiveness might result if an end product of an intact estrogen response system were measured instead of the initial hormone binding step. Progesterone receptor (PgR) has been investigated in this regard since it can be readily measured in human breast tumors and there is clear evidence in experimental breast tumor model systems that PgR is under acute estrogen control. PgR is rarely found in ER- metastatic breast tumors but is present in approximately 59% of ER+ metastatic tumors, especially in those tumors with high levels of ER. Preliminary clinical correlation of ER, PgR and response to endocrine therapy is encouraging. The response rate is significantly higher if the tumor contains both ER and PgR than if the tumor contains ER alone.

Adrenalectomy↗
PubMed1976

Appraising current therapy for breast cancer. 3. Hormonal manipulation and chemotherapy.

Hormonal manipulation and chemotherapy used as adjuvants to surgery are aimed at controlling systemic micro-metastases from breast cancer. Primary hormonal manipulation consists of oophorectomy (for premenopausal women) or hormone administration. Hormone receptors, which are sometimes present in tumors, are now being measured and tested for their predictive value as to which tumors will respond to manipulation. Systemic chemotherapy has been used for years, but no drug that is specific against mammary tumors has yet been discovered. New drugs or combinations of older drugs are constantly being tested. To acquire a good data base for future decisions, systemic chemotherapy should be administered and patients followed up according to carefully constructed protocols.

Breast Neoplasms↗
PubMed1975

Hormone treatment of breast cancer.

Alteration of the hormonal milieu is still one of the major and most successful methods for treating advanced breast cancer. With the exception of the use of thyroid hormone in conjunction with corticosteroids, we are not aware of any proved advantageous combination of hormonal agents that improves the objective regression rates in advanced breast cancer.

Adrenal Cortex Hormones↗
PubMed1975

Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group.

A clinical trial of androgen and antimetabolite therapy of advanced female breast cancer was conducted in 110 patients by the Cooperative Breast Cancer Group. An objective regression rate of 20% was achieved in women receiving oral testolactone, 6% in patients given intravenous fluorouracil alone, and 14% when the androgen and antimetabolite were administered together. This randomized trial according to the CBCG protocol did not produce the high regression rate noted previously in a nonrandomized, nonprotocol evaluation of these drugs.

Administration, Oral↗
PubMed1975

Spontaneous adenocarcinomas of the ventral prostate of aged A X C rats.

Spontaneous adenocarcinomas of the ventral prostate were present in 7 of 41 aged (34- to 37-month-old), virgin, untreated male A X C rats. The only consistent gross evidence of possible neoplastic involvement was intraprostate hemorrhage. The principally intraglandular neoplasms were composed of markedly anaplastic epithelial cells which retained a moderate propensity to form glandular patterns. The nuclei of the neoplastic cells were pleomorphic, vesiculated, enlarged, and hyperchromatic. Mitotic figures were frequent. Interglandular connective tissue was invaded in one rat; however, metastases were not demonstrated.

Adenocarcinoma↗